Introduction {#s0001}
============

South Africa is the global epicentre of the human immunodeficiency virus (HIV) pandemic, with an antenatal prevalence of 31%.^[@CIT0001]^ Human immunodeficiency virus-infected women are at increased risk of delivering low birth weight and/or preterm infants^[@CIT0002]^ and of transmitting infection to their infants. HIV transmission is higher in the absence of maternal antiretroviral therapy (ART);^[@CIT0003],[@CIT0004],[@CIT0005],[@CIT0006]^ greater with higher maternal viral load; greater with worsening immunosuppression (low CD4 count);^[@CIT0003],[@CIT0004],[@CIT0006]^ and is increased in the presence of maternal infections such as tuberculosis and sexually transmitted disease.^[@CIT0007]^ Increased permeability of the intestinal mucosal barrier in preterm infants further increases the risk of mother-to-child transmission (MTCT).^[@CIT0004],[@CIT0006]^ These infants are also at risk of necrotising enterocolitis (NEC) if formula feeds are administered in an effort to reduce MTCT.^[@CIT0008]^ Mother's own milk (MOM) is crucial to the survival of preterm infants.^[@CIT0009]^ The risk and benefit to VLBW HIV-exposed infants receiving prevention of mother-to-child transmission (PMTCT) interventions and 'raw' MOM (rMOM) is unclear. Preterm and VLBW infants receiving rMOM have fewer infections and less NEC.^[@CIT0008],[@CIT0009]^ Whether this is true for HIV-exposed preterm and VLBW infants has not been studied.

PMTCT programmes in South Africa before 2002 were limited because of governmental AIDS denialism and concerns related to ART toxicity.^[@CIT0010]^ In 2002, a Constitutional Court ruling mandated rolling-out of a PMTCT programme.^[@CIT0011]^ Reports of MTCT of HIV in VLBW infants followed,^[@CIT0012],[@CIT0013],[@CIT0014],[@CIT0015],[@CIT0016],[@CIT0017]^ but these failed to determine the safest feeding choice in such infants. The feeding regimens in these studies included exclusive formula feeding (EFF) in line with the National PMTCT programme at the time,^[@CIT0018],[@CIT0019]^ exclusive donor breast milk (DBM) (holder pasteurised) and heat-treated MOM (Pretoria pasteurised or flash-heated).^[@CIT0020],[@CIT0021]^

Annual studies reporting on MTCT in infants ≤ 1500 g from 2005 to 2007 noted HIV transmission rates of 14.9%,^[@CIT0012]^ 19.0%^[@CIT0013]^ and 10.0%,^[@CIT0014]^ respectively. At this time, the implementation of ART for PMTCT in South Africa was inconsistently applied ([Table 1](#T0001){ref-type="table"}). Subsequently (2008--2015), MTCT declined from 7.6% to 0.0%^[@CIT0015],[@CIT0016],[@CIT0017]^ when PMTCT became the standard of care ([Table 1](#T0001){ref-type="table"}). This included improved infant regimens at and post-delivery^[@CIT0018],[@CIT0019],[@CIT0022],[@CIT0023],[@CIT0024]^ and the provision of maternal combination ART (cART) to pregnant and breastfeeding women.^[@CIT0023]^ No infants included in these studies (*n* = 289) received rMOM from birth.^[@CIT0015],[@CIT0016],[@CIT0017]^

###### 

South African studies reporting on human immunodeficiency virus transmission by postnatal age in infants ≤ 1500 g birth weight.

  Year Hospital                                               Birth weight (*n*)                               Maternal ART                                                                       Infant regimen            Infant feeding                                          MTCT of HIV
  ----------------------------------------------------------- ------------------------------------------------ ---------------------------------------------------------------------------------- ------------------------- ------------------------------------------------------- ----------------------------------------
  **2003--2005** Tygerberg^[@CIT0012]^                        \< 1500 g (141)                                  sdNVP during labour or AZT from 34 weeks gestation with sdNVP during labour: 72%   sdNVP or sdNVP+AZT: 99%   Heat-treated EBM/DBM/EFF                                14.9% by 14 weeks
  **2006--2007** Chris Hani Baragwanath^[@CIT0013]^           \< 1500 g (26)                                   cART: 1% NVP before delivery: 36%                                                  sdNVP: 73%                Not documented                                          19% by 6 weeks (95% CI: 7% -- 40%)
  **2006--2007** Kalafong^[@CIT0014]^                         ≤ 1500 g (83)                                    sdNVP: 37% cART: 13% No ART: 50%                                                   sdNVP: 100%               Heat-treated EBM/EFF                                    10% by 6 weeks
  **2007--2008** Tygerberg^[@CIT0015]^                        ≤ 1500 g (185)                                   cART: 17% AZT/NVP before delivery: 28% AZT/NVP during labour: 43% No ART: 15%      AZT: 100%                 Heat-treated EBM/DBM/EFF                                7.6% by ≥ 2 weeks
  **2010--2011** Groote Schuur^[@CIT0016]^                    ≤ 1000 g (37)                                    Some ART: 72% (ART \>1 month before delivery: 44%)                                 NVP or sdNVP+AZT: 100%    Heat-treated EBM/DBM/EFF                                2.7% by 6 weeks (95% CI: 0.7% --14.1%)
  **2014--2015** Groote Schuur and New Somerset^[@CIT0017]^   \< 1500 g (67)[†](#tf1-1){ref-type="table-fn"}   ART \>1 month before delivery: 72% ART \<1 month before delivery: 9% No ART: 13%   NVP+AZT: 100%             Heat-treated EBM until infant can breastfeed/DBM/ EFF   0% by 6 weeks

ART, antiretroviral therapy; AZT, azidothymidine; DBM, donor breast milk; EFF, exclusive formula feeding; cART, combination antiretroviral therapy; NVP, nevirapine; sdNVP, single dose nevirapine; PCR, polymerase chain reaction; EBM, expressed breast milk.

Number of infants calculated from the statement by the authors that 87% of the cohort that was negative at birth (*n* = 77) was tested at 6 weeks of age.

Most HIV-exposed preterm infants prior to initiation of modern PMTCT programmes received EFF, as did their term counterparts.^[@CIT0018],[@CIT0019]^ Subsequently, the safety of heat-treated expressed MOM was confirmed,^[@CIT0020],[@CIT0021]^ and this became the feeding choice for hospitalised preterm infants in many facilities. Although affordable,^[@CIT0020],[@CIT0021]^ heat-treated MOM is labour-intensive in a hospital setting and for mothers after discharge. Also, it remained unclear whether non-HIV-related benefits of MOM were lost through the heat treatment.

Study objective {#s0002}
===============

A retrospective, observational audit was undertaken to determine the cumulative incidence of peripartum HIV transmission at 4--6 weeks of age in HIV-exposed VLBW infants, who received infant prophylaxis according to the National PMTCT programme of 2010^[@CIT0019],[@CIT0022]^ and 'predominantly' raw MOM (prMOM) (see Study Population section for the definition of prMOM).

Material and methods {#s0003}
====================

Setting {#s0003.1}
-------

This study was performed in the Neonatal Unit of Kalafong Provincial Tertiary Hospital, South Africa. The neonatal unit comprises 30 beds, which include 6 neonatal intensive care beds. There are approximately 5900 deliveries per year at Kalafong Provincial Tertiary Hospital, with a maternal HIV prevalence of approximately 18%.

Study population {#s0003.2}
----------------

The study population was identified from ward registers. The start of this study, 01 March 2010, coincided with the implementation of the National 2010 PMTCT guideline. Records of patients admitted to the unit in the subsequent 36 consecutive months were audited. Breast milk was prescribed to all infants admitted to the neonatal unit and supplemented by DBM if MOM was insufficient.

Infants were included if they were HIV-exposed, that is, born to an HIV-positive mother and received prMOM, that is, at least two-thirds of the total enteral volume, over the study period. The remaining one-third enteral fluid volume was DBM and was given with infant antiretroviral prophylaxis. The latter was daily nevirapine from birth until at least 6 weeks of age. A surveillance HIV-PCR was checked at 6 weeks as per the 2010 National PMTCT programme.^[@CIT0019],[@CIT0022]^ ([Table 2](#T0002){ref-type="table"}).

###### 

Maternal antiretroviral therapy, infant prophylaxis and feeding regimens recommended by the South African national prevention of mother-to-child transmission programme of 2010 for human immunodeficiency virus-positive women during pregnancy and after delivery and their human immunodeficiency virus-exposed infants.

  Variable                                       PMTCT programme                                                                           
  ---------------------------------------------- ----------------------------------------------------------------------------------------- --------------------------------------------------
  **Maternal ART regimen**                                                                                                                 
  CD4 \> 350 cells/mm^3^                         Dual therapyn[†](#tf2-1){ref-type="table-fn"}                                             Dual therapy[†](#tf2-1){ref-type="table-fn"}
  CD4 ≤ 350 cells/mm^3^ or stage 3 or 4 HIV      Lifelong cART[‡](#tf2-2){ref-type="table-fn"}                                             Lifelong cART[‡](#tf2-2){ref-type="table-fn"}
  **Infant prophylaxis**                                                                                                                   
  EFF                                            NVP for 6 weeks                                                                           NVP for 6 weeks
  Breastfeeding without maternal lifelong cART   NVP until 1 week post-cessation of breastfeeding                                          NVP until 1 week post-cessation of breastfeeding
  Breastfeeding with maternal lifelong cART      NVP for 6 weeks                                                                           NVP for 6 weeks
  **Infant feeding regimens**                    EFF if the AFASS criteria are met Exclusive breastfeeding if AFASS criteria are not met   Exclusive breastfeeding for all infants

AFASS, acceptable, feasible, affordable, safe, sustainable; AZT, azidothymidine; cART, combination antiretroviral therapy; EFF, exclusive formula feeding; FTC, emtricitabine; NVP, nevirapine; TDF, tenofovir.

Dual therapy: AZT from 14 weeks gestation, followed by three-hourly AZT and single dose NVP during labour, with a single dose of TDF and FTC after delivery (ART discontinued after delivery).

Lifelong cART: TDF + lamivudine/FTC + NVP/efavirenz (continued after delivery).

Deviations from the surveillance regimen^[@CIT0019],[@CIT0022]^ were indicated in some infants. These included HIV-PCR testing at 'non-routine' times, for example, within 72 h after birth to diagnose congenital infection; before 6 weeks of age in the event of clinical signs suggestive of HIV infection; and should discharge occur before 4 weeks of age to minimise the number who might not return and so be lost to follow-up. All HIV-PCR test results were accessed from patient files and the National Health Laboratory Service (NHLS) database.

Definitions {#s0003.3}
-----------

### Congenital infection {#s3c1}

*In utero* acquisition of HIV (congenital infection) was diagnosed when an HIV-PCR was positive within 72 h of birth.

### Peripartum infection {#s3c2}

The MTCT of HIV during the peripartum period was defined as HIV acquisition during labour, delivery or while receiving prMOM and nevirapine (NVP) prophylaxis. It was diagnosed when an HIV-PCR test was negative within 72 h after birth yet positive at 4--6 weeks. In the absence of an early HIV-PCR, peripartum infection was excluded if the HIV-PCR was negative at 4--6 weeks.

Exclusion criteria {#s0003.4}
------------------

Infants were excluded if death occurred before 4 weeks of age, azidothymidine (AZT) was used as PMTCT, feeds were exclusively DBM or EFF, no HIV-PCR result was available at 4--6 weeks of age, admission to the neonatal unit occurred after 72 h of life, HIV was deemed to have been acquired *in utero* and clinical records were missing or incomplete ([Figure 1](#F0001){ref-type="fig"}).

![Flow chart detailing exclusions.](HIVMED-20-912-g001){#F0001}

Background {#s0003.5}
----------

### Infant feeding regimens {#s3e1}

Although free tins of formula were provided for HIV-exposed infants who complied with the acceptable, feasible, affordable, safe and sustainable (AFASS) feeding criteria,^[@CIT0021]^ breastfeeding was officially adopted in August 2011 (Tshwane Declaration) as the feeding regimen of choice for all infants, including those who were HIV-exposed^[@CIT0025]^ as breast milk was shown to be safe in these infants provided they received PMTCT^[@CIT0026]^ ([Table 2](#T0002){ref-type="table"}).

### Maternal antiretroviral therapy regimens {#s3e2}

The National PMTCT programme of 2010 used the maternal CD4 count and HIV staging to determine maternal antenatal and postnatal ART regimens^[@CIT0019],[@CIT0022],[@CIT0027]^ ([Table 2](#T0002){ref-type="table"}).

### Exposure of infants to maternal antenatal antiretroviral therapy {#s3e3}

Duration of exposure to maternal antenatal ART (lifelong cART or dual therapy) was defined, for the purpose of this study, as optimal (≥ 4 weeks), suboptimal (\< 4 weeks) or no ART.

### Infant prophylaxis {#s3e4}

All infants were initiated on NVP after delivery, which was continued for at least 6 weeks. A weight-based dosing regimen, as recommended by the World Health Organization,^[@CIT0028]^ was adopted for infants weighing \< 1800 g: 2 mg/kg daily for the first 2 weeks of life and 4 mg/kg thereafter.^[@CIT0029]^

Data analysis {#s0003.6}
-------------

Statistical analysis was performed using Stata statistical software 2017 (Release 15.1, StataCorp LLC, College Station, US). Continuous data were expressed as medians and ranges and categorical data as frequencies and percentages. Cumulative incidence and 95% confidence intervals were determined using Poisson regression.

Ethical consideration {#s0004}
=====================

The study protocol was approved by the Ethics Committee of the Faculty of Health Sciences of the University of Pretoria, South Africa (Ethics approval number 351/2013).

Results {#s0005}
=======

Over the 3-year period from 01 March 2010 to 28 February 2013, 3790 newborn infants were admitted to the Neonatal Unit, of whom 3774/3790 (99.58%) had a documented birth weight. Of these infants, 690/3774 (18.28%) had a birth weight ≤ 1500 g; 404/690 (58.55%) of these were not HIV-exposed; 219/690 (31.74%) were HIV-exposed; and a further 67/690 (9.71%) had no documented maternal HIV test result.

Study population and exclusions {#s0005.1}
-------------------------------

The HIV-exposed infants (219/690) were the preliminary study population. As per protocol, 139/219 infants were excluded, as shown in [Figure 1](#F0001){ref-type="fig"}. A sample of 80/219 HIV-exposed infants remained and formed the final study population. The details of the 39 infants who died and were consequently excluded from the study are also shown in [Figure 1](#F0001){ref-type="fig"}.

Maternal data of the study population {#s0005.2}
-------------------------------------

The maternal population totalled 72 mothers: 8/80 infants were four twin pairs. Of these mothers, 61/72 (84.72%) received antenatal care during pregnancy. All had non-reactive rapid plasma reagin (RPR) tests for syphilis, while 7/72 (9.72%) received treatment for tuberculosis (TB). The demographics of the HIV-infected mothers is shown in [Table 3](#T0003){ref-type="table"}. The median CD4 count was 272 cells/mm^[@CIT0003]^ (range 8--1097 cells/mm^[@CIT0003]^), and the median HIV viral load was 7191 copies/mL (range 0--68 952 copies/mL). It should be noted that only 77.78% (56/72) of HIV-infected women were receiving ART during their pregnancy.

###### 

Maternal human immunodeficiency virus characteristics

  Variable                        All mothers *N* = 72 (%)   MTCT absent *N* = 70 (%)                MTCT present *N* = 2 (%)                   
  ------------------------------- -------------------------- --------------------------------------- -------------------------- ------- ------- -------
  **Timing of HIV diagnosis**     **72**                     **-**                                   **70**                     **-**   **2**   **-**
  Before pregnancy                7                          9.72                                    7                          10.0    \-      \-
  During pregnancy                15                         20.83                                   15                         21.42   \-      \-
  At delivery                     5                          6.94                                    4                          5.71    1       50.0
  Post-delivery                   3                          4.17                                    2                          2.86    **-**   **-**
  Not documented                  42                         58.33                                   42                         60.0    1       50.0
  **CD4 count (cells/mm^3^)**     **71**                     **-**                                   **69**                     **-**   **2**   **-**
  ≤ 350                           42                         59.15                                   41                         59.42   1       50.0
  \> 350                          29                         40.85                                   28                         40.58   1       50.0
  **HIV VL (copies/mL)**          **72**                     **-**                                   **70**                     **-**   **2**   **-**
  \< 1000                         3                          4.17                                    3                          4.29    **-**   **-**
  ≥ 1000                          9                          12.50                                   8                          11.42   1       50.0
  Not determined                  60                         83.33                                   59                         84.29   1       50.0
  **Antenatal ART**               **72**                     **-**                                   **70**                     **-**   **2**   **-**
  Any                             56                         77.78                                   56                         80.0    **-**   **-**
  Lifelong cART                   33                         45.83                                   33                         47.14   **-**   **-**
  Dual therapy                    23                         31.94                                   23                         32.86   **-**   **-**
  None                            15                         20.83[†](#tf3-1){ref-type="table-fn"}   13                         18.57   2       100
  Not documented                  1                          1.39                                    1                          1.43    **-**   **-**
  **Duration of antenatal ART**   **56**                     **-**                                   **56**                     **-**   **0**   **-**
  ≥ 4 weeks                       33                         58.92                                   33                         58.92   **-**   **-**
  Lifelong cART                   25                         44.64                                   25                         44.64   **-**   **-**
  Dual therapy                    8                          14.29                                   8                          14.29   **-**   **-**
  \< 4 weeks                      11                         19.64                                   11                         19.64   **-**   **-**
  Not documented                  12                         21.43                                   12                         21.43   **-**   **-**
  **Postnatal lifelong cART**     **72**                     **-**                                   **70**                     **-**   **2**   **-**
  Continued after delivery        33                         45.83                                   33                         47.14   **-**   **-**
  Initiated after delivery        5                          6.94                                    4                          5.71    1       50.0
  Not indicated                   33                         45.83                                   32                         45.71   1       50.0
  Not documented                  1                          1.39                                    1                          1.43    **-**   **-**

ART, antiretroviral therapy; HIV, human immunodeficiency virus; VL, viral load; MTCT, mother-to-child HIV-transmission.

One twin pair.

Clinical characteristics of the study population (*n* = 80) {#s0005.3}
-----------------------------------------------------------

Infant median weight was 1130 g (range 510--1500 g) and the median gestational age was 30 weeks (range 25--38 weeks). Additional data are shown in [Table 4](#T0004){ref-type="table"}. During pregnancy, only 78.75% (63/80) of infants had any antenatal ART exposure. Twenty per cent had no exposure. The antenatal ART exposure of one infant was undocumented. After delivery, all infants (*n* = 80) received both postnatal NVP and prMOM until discharge ([Figure 2](#F0002){ref-type="fig"}).

###### 

Infant characteristics.

  Clinical features                                  All infants *N* = 80 (%)   HIV-exposed uninfected infants *N* = 78 (%)   HIV-infected infants *N* = 2 (%)                   
  -------------------------------------------------- -------------------------- --------------------------------------------- ---------------------------------- ------- ------- -------
  **Pregnancy**                                      **80**                     \-                                            **78**                             **-**   **2**   **-**
  Singleton                                          60                         75.0                                          58                                 74.36   2       100
  Multiple (twin)                                    20                         25.0                                          20                                 25.64   \-      \-
  **Gender**                                         **80**                     **-**                                         **78**                             **-**   **2**   **-**
  Female                                             46                         57.50                                         45                                 57.69   1       50.0
  Male                                               34                         42.50                                         33                                 42.31   1       50.0
  **Mode of delivery**                               **78**                     **-**                                         **77**                             **-**   **1**   **-**
  Caesarean section                                  43                         55.13                                         43                                 55.84           
  Vaginal delivery                                   30                         38.46                                         29                                 37.66   1       100
  BBA                                                5                          6.41                                          5                                  6.49    \-      \-
  **Place of delivery**                              **79**                     **-**                                         **78**                             **-**   **1**   **-**
  Inborn                                             69                         87.34                                         68                                 87.18   1       100
  Outborn (including BBA)                            10                         12.66                                         10                                 12.82   \-      \-
  **Amniotic membranes**                             **49**                     **-**                                         **49**                             **-**   **0**   **-**
  Intact                                             29                         59.18                                         29                                 59.18   \-      \-
  Ruptured \< 24 h                                   9                          18.37                                         9                                  18.37   \-      \-
  Ruptured ≥ 24 h[†](#tf4-1){ref-type="table-fn"}    11                         22.45                                         11                                 22.45   \-      \-
  **Placental histology**                            **16**                     **-**                                         **16**                             **-**   **0**   **-**
  Acute chorioamnionitis                             9                          56.25                                         9                                  56.25   \-      \-
  **Tuberculosis exposed**                           **8**                      **-**                                         **8**                              **-**   **0**   **-**
  Received treatment                                 3                          37.50                                         3                                  37.50           
  **ART**                                                                                                                                                                        
  **Exposure to antenatal ART**                      **80**                     **-**                                         **78**                             **-**   **2**   **-**
  Yes                                                63                         78.75                                         63                                 80.77   \-      \-
  No                                                 16                         20.0                                          14                                 17.95   2       100
  Not documented                                     1                          1.25                                          1                                  1.28    \-      \-
  **Exposure to ≥ 4 weeks antenatal ART**            **49**                     **-**                                         **49**                             **-**   **0**   **-**
  Yes                                                37                         75.51                                         37                                 75.51   \-      \-
  Lifelong cART                                      27                         55.10                                         27                                 55.10   \-      \-
  Dual therapy                                       10                         20.41                                         10                                 20.41   \-      \-
  **Exposure to postnatal maternal cART**            **80**                     **-**                                         **78**                             **-**   **2**   **-**
  Yes                                                40                         50.0                                          40                                 51.28   \-      \-
  No                                                 39                         48.75                                         37                                 47.44   2       100
  Not documented                                     1                          1.25                                          1                                  1.28    \-      \-
  **Infant prophylaxis**                             **80**                     **-**                                         **78**                             **-**   **2**   **-**
  Yes                                                80                         100                                           78                                 100     2       100
  **Feeding**                                        **80**                     \-                                            **78**                             **-**   **2**   **-**
  prMOM                                              80                         100                                           78                                 100     2       100
  Supplemental DBM[‡](#tf4-2){ref-type="table-fn"}   21                         26.25                                         21                                 26.92   \-      \-
  **HIV-PCR**                                        **80**                     **-**                                         **78**                             **-**   **2**   **-**
  Negative                                           78                         97.50                                         78                                 100     \-      \-
  Positive                                           2                          2.50                                          \-                                 \-      2       100

BBA, born before arrival; cART, combination antiretroviral therapy; DBM, donor breast milk; NVP, nevirapine; PCR, polymerase chain reaction; prMOM, predominantly raw mother's own milk.

Prolonged ROM is defined as ROM ≥ 24 h.

Less than one-third of the total enteral intake.

![The safety of 'raw' mother's own milk in human immunodeficiency virus-exposed very low birth weight infants.](HIVMED-20-912-g002){#F0002}

### Postnatal prophylaxis {#s5c1}

All 80 infants were hospitalised after birth and received supervised daily NVP until discharge. The majority of infants (67/80) received the first dose of NVP within 24 h of birth. Seven infants received it after 24 h (range 30--84 h). The timing of the first dose was not recorded for six infants. Just more than half of the infants (41/80) received NVP at the recommended daily dose of 2 mg/kg, with doses varying between 2 mg/kg and 10 mg/kg (median 2 mg/kg), but never exceeding a total daily dose of 10 mg.

In addition to NVP, 40/80 (50.0%) infants were also exposed to maternal lifelong cART during breastfeeding.

### Feeding regimen with mother's own milk {#s5c2}

In keeping with the exclusive breastfeeding policy of the Neonatal Unit, MOM was prescribed for all infants after birth. Three-quarters, viz. 59/80 (73.8%) of infants, received rMOM exclusively until discharge. The remainder, viz. 21/80, required supplementation with DBM. The median proportion of the volume of DBM intake of the 21/80 infants was 8.96% (range 1.67% -- 33.33%) of the total enteral intake. No infant received formula milk.

Mother-to-child transmission of human immunodeficiency virus {#s0005.4}
------------------------------------------------------------

A definitive HIV-PCR was performed on 78/80 infants by 4--6 weeks of age to rule out peripartum acquisition of HIV; *n* = 45/78 infants tested negative before discharge; 33/78 infants tested negative at follow-up, viz. 67/78 at 6 weeks, 7/78 at 5 weeks and 4/78 at 4 weeks of age. Two infants tested positive: one on day 9 and the other on day 20 of life. These HIV-PCR tests were performed earlier because clinical signs suggested active HIV infection. Human immunodeficiency virus infection in these two infants was confirmed with a second (follow-up) HIV-PCR, and they were initiated on lifelong cART. Neither had an HIV-PCR within 72 h of birth, so *in utero* HIV infection cannot be excluded. Their birth weights were 1120 g and 1400 g, respectively. Both were on NVP prophylaxis and prMOM from birth. Neither had been exposed to maternal ART before birth. Fourteen (14/78) other HIV-exposed but uninfected (HEU) infants remained uninfected despite the absence of exposure to maternal ART prior to birth ([Table 4](#T0004){ref-type="table"}).

The time of HIV acquisition in the two infected infants (namely *in utero* as opposed to peripartum) could not be determined with certainty. Therefore, the cumulative incidence of peripartum HIV transmission by 4--6 weeks of age in the study population is expressed as ranging between 0% and 2.5%. It would be 0% had both these infants acquired HIV *in utero*, 1.27% (95% CI: 0.2--8.9) had one infant acquired HIV during the peripartum period, and 2.5% (95% CI: 0.6--9.9) had both acquired HIV during the peripartum period ([Figure 3](#F0003){ref-type="fig"}).

![Three scenarios related to cumulative incidence of peripartum human immunodeficiency virus transmission by 4--6 weeks.](HIVMED-20-912-g003){#F0003}

Discussion {#s0006}
==========

The cumulative incidence of peripartum HIV infection in VLBW infants by 4--6 weeks receiving the National PMTCT programme of 2010 ^[@CIT0019],[@CIT0022]^ in addition to prMOM is 2.5%. This is comparable to the MTCT of 2.7% in a more vulnerable cohort of extremely low birth weight South African infants at 6 weeks.^[@CIT0016]^ This cohort, studied when the National PMTCT programme of 2010^[@CIT0019],[@CIT0022]^ was operational, did not receive rMOM.^[@CIT0016]^ The VLBW infants in our study received prMOM and its additional nutritional and immunological advantages with seemingly no increased risk of MTCT. This finding lends support for the contention that exclusive breastfeeding of HIV-exposed infants^[@CIT0003]^ and their VLBW counterparts is safe in the context of antiretroviral prophylaxis.

As previously documented, 690 of the 3774 infants (18.28%) admitted to the Neonatal Unit at Kalafong Provincial Tertiary Hospital were VLBW, 219 being HIV-exposed. Their risk of being already HIV-infected at the time of birth (*in utero* HIV acquisition) or acquiring the infection during the peripartum period could be minimised by timeous antenatal as well as postnatal maternal ART. Providing the infant with additional ART prophylaxis after birth should further reduce the risk of peripartum HIV transmission, particularly via breast milk. This directive was mandated by the National PMTCT programme of 2010,^[@CIT0019],[@CIT0022]^ at the time of this study, however was not reliably applied especially during the antenatal period. At least 15/72 women received no ART during pregnancy, which increased the risk of *in utero* and peripartum infection in 16 infants in the study population (one mother had twins). Only two of these 16 infants acquired HIV infection, while none of the infants exposed to antenatal ART acquired HIV infection, although receiving prMOM in the presence of postnatal NVP prophylaxis ([Figure 2](#F0002){ref-type="fig"}). These results suggest that NVP prophylaxis may be effective in preventing early transmission of HIV in VLBW infants receiving prMOM; however, as this is the first study reporting on the safety of prMOM in VLBW infants, this observation should be confirmed by larger studies.

Limitations {#s0007}
===========

Although all infants received prophylaxis, it was carried out inconsistently. Some infants did not receive the first NVP dose immediately after delivery, and in almost half, the weight-based NVP regimen was not adhered to. Notably, only 2/42 infants with suboptimal or no antenatal ART exposure acquired HIV infection in the presence of prMOM. The inconsistencies in the practical implementation of the National PMTCT programme of 2010^[@CIT0019],[@CIT0022]^ at clinic and hospital level demonstrate the importance of correct emphasis when training healthcare workers.

Lack of maternal ART may have contributed to HIV transmission in the two HIV-infected infants in this study because neither of the mothers received antenatal or postnatal ART before the infants were diagnosed with HIV infection.

By virtue of the retrospective nature of this study, limitations exist. Reduced infant numbers (*n* = 80) resulting from various exclusions ([Figure 1](#F0001){ref-type="fig"}) was the predominant limitation. The largest number of exclusions was for undocumented maternal HIV status (67/690), and no traceable infant HIV-PCR result at ≥ 4 weeks of age (54/219). No long-term follow-up HIV results were available for the 80 included infants, so the overall HIV transmission rate is unknown.

Although the results may be confounded by the 39 deaths prior to 4 weeks of age, the majority of these deaths occurred before 7 days of life (32/39) and are likely to have been immaturity related. However, the possibility of peripartum HIV infection in the late deaths (7/39) cannot be excluded.

Other confounding factors include the possibility of false-negative HIV-PCR tests by 4--6 weeks of age as a result of incomplete viral suppression caused by maternal ART exposure and/or infant prophylaxis.^[@CIT0030]^

Conclusion and recommendations {#s0008}
==============================

Viral suppression by antenatal ART followed by infant prophylaxis decreases the risk of MTCT in preterm infants in the presence of rMOM and is likely to protect from life-threatening infection in this group of special -- 'key population' -- patients. Additional personal and public health consequences of breastfeeding such as bonding and long-term successful lactation are of importance to HIV-positive mothers and their children.

Addendum {#s0009}
========

The latest National PMTCT programme (2017)^[@CIT0024]^ differs from the 2010 programme^[@CIT0019],[@CIT0022]^ ([Table 2](#T0002){ref-type="table"}) as follows: Maternal lifelong cART is initiated immediately at HIV diagnosis, irrespective of the CD4 count or HIV staging. Infant PMTCT prophylaxis (drugs and duration) is dependent on maternal factors, with risk classified as low or high. 'Low-risk' infants (maternal cART since conception; cART \> 4 weeks prior to delivery with a viral load \< 1000 copies/mL) receive NVP for 6 weeks, and 'high-risk' infants (newly diagnosed maternal HIV; cART \< 4 weeks; viral load \> 1000 copies/mL) receive dual therapy (NVP plus AZT) for 12 weeks. Breastfeeding is recommended for all HIV-exposed infants ('low risk' and 'high risk'), except for those whose mothers are failing second-line or third-line ART regimens.
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